Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPPI: Pomalidomide in Chronic Hepatitis B Virus Infection
2025-521030-29-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Aug 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pomalidomide in Chronic Hepatitis B (CHB), sponsored by Central Denmark Region. Primary endpoints: Treatment-emergent grade ≥3 adverse events related to pomalidomide and All treatment-emergent adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
pomalidomide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2025-521030-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521030-29-00.